190 related articles for article (PubMed ID: 35390135)
1. Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
Phillips T; Chan H; Tam CS; Tedeschi A; Johnston P; Oh SY; Opat S; Eom HS; Allewelt H; Stern JC; Tan Z; Novotny W; Huang J; Trotman J
Blood Adv; 2022 Jun; 6(11):3472-3479. PubMed ID: 35390135
[TBL] [Abstract][Full Text] [Related]
2. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Opat S; Tedeschi A; Linton K; McKay P; Hu B; Chan H; Jin J; Sobieraj-Teague M; Zinzani PL; Coleman M; Thieblemont C; Browett P; Ke X; Sun M; Marcus R; Portell CA; Ardeshna K; Bijou F; Walker P; Hawkes EA; Mapp S; Ho SJ; Talaulikar D; Zhou KS; Co M; Li X; Zhou W; Cappellini M; Tankersley C; Huang J; Trotman J
Clin Cancer Res; 2021 Dec; 27(23):6323-6332. PubMed ID: 34526366
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
[TBL] [Abstract][Full Text] [Related]
4. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Huang J; Novotny W; Kim P; Yu Y; Wu B; Zhu J
Blood; 2022 May; 139(21):3148-3158. PubMed ID: 35303070
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
6. Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies.
Xu W; Yang S; Tam CS; Seymour JF; Zhou K; Opat S; Qiu L; Sun M; Wang T; Trotman J; Pan L; Gao S; Zhou J; Zhou D; Zhu J; Song Y; Hu J; Feng R; Huang H; Su D; Shi M; Li J
Adv Ther; 2022 Sep; 39(9):4250-4265. PubMed ID: 35900694
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
Soumerai JD; Diefenbach CS; Jagadeesh D; Asch A; Kumar A; Tsai ML; Jandl TA; Lossos IS; Kenkre VP; Awan F; Novotny W; Huang J; Miao L; Rajagopalan P; Ghalie RG; Zelenetz AD
Br J Haematol; 2024 May; 204(5):1762-1770. PubMed ID: 38500476
[TBL] [Abstract][Full Text] [Related]
8. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Noy A; de Vos S; Thieblemont C; Martin P; Flowers CR; Morschhauser F; Collins GP; Ma S; Coleman M; Peles S; Smith S; Barrientos JC; Smith A; Munneke B; Dimery I; Beaupre DM; Chen R
Blood; 2017 Apr; 129(16):2224-2232. PubMed ID: 28167659
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza-Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E
J Clin Oncol; 2011 Mar; 29(9):1198-203. PubMed ID: 21300924
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Opat S; Tedeschi A; Hu B; Linton KM; McKay P; Leitch S; Coleman M; Zinzani PL; Jin J; Sun M; Sobieraj-Teague M; Browett P; Ke X; Thieblemont C; Ardeshna K; Bijou F; Walker P; Hawkes EA; Ho SJ; Zhou K; Liang Z; Xu J; Tankersley C; Delarue R; Co M; Trotman J
Blood Adv; 2023 Nov; 7(22):6801-6811. PubMed ID: 37682792
[TBL] [Abstract][Full Text] [Related]
11. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Neelapu SS; Chavez JC; Sehgal AR; Epperla N; Ulrickson M; Bachy E; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Oluwole OO; Yakoub-Agha I; Khanal R; Rosenblatt J; Korn R; Peng W; Lui C; Wulff J; Shen R; Poddar S; Jung AS; Miao H; Beygi S; Jacobson CA
Blood; 2024 Feb; 143(6):496-506. PubMed ID: 37879047
[TBL] [Abstract][Full Text] [Related]
12. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.
Tam CS; Quach H; Nicol A; Badoux X; Rose H; Prince HM; Leahy MF; Eek R; Wickham N; Patil SS; Huang J; Prathikanti R; Cohen A; Elstrom R; Reed W; Schneider J; Flinn IW
Blood Adv; 2020 Oct; 4(19):4802-4811. PubMed ID: 33022066
[TBL] [Abstract][Full Text] [Related]
13. Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.
Yang H; Xiang B; Song Y; Zhang H; Zhao W; Zou D; Lv F; Guo W; Liu A; Li C; Tan Z; Liu Y; Fu L; Guo H; Novotny W; Huang J; Li Y
Blood Adv; 2022 Mar; 6(6):1629-1636. PubMed ID: 34638136
[TBL] [Abstract][Full Text] [Related]
14. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.
Davids MS; Roberts AW; Kenkre VP; Wierda WG; Kumar A; Kipps TJ; Boyer M; Salem AH; Pesko JC; Arzt JA; Mantas M; Kim SY; Seymour JF
Clin Cancer Res; 2021 Sep; 27(17):4690-4695. PubMed ID: 34083230
[TBL] [Abstract][Full Text] [Related]
15. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
Tam CS; Opat S; Simpson D; Cull G; Munoz J; Phillips TJ; Kim WS; Rule S; Atwal SK; Wei R; Novotny W; Huang J; Wang M; Trotman J
Blood Adv; 2021 Jun; 5(12):2577-2585. PubMed ID: 34152395
[TBL] [Abstract][Full Text] [Related]
16. Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Deng L; Li Z; Zhang H; Huang H; Hu J; Liu L; Liu T; Jin J; Zhu Z; Li W; Huang Z; Huang W; Zhou K; Yang H; Zhang M; Ding K; Zhou H; Hu Y; Shuang Y; Cao J; Gao S; Li D; Sun Z; Zhang Q; Yi S; Ji C; Zhang L; Hou C; Du Y; Wang W; Zhao R; Song Y; Zhu J
Am J Hematol; 2023 Nov; 98(11):1742-1750. PubMed ID: 37647123
[TBL] [Abstract][Full Text] [Related]
17. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials.
Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Zhou D; Tam CS; Simpson D; Wang M; Phillips TJ; Opat S; Huang Z; Lu H; Song Y; Song Y
J Hematol Oncol; 2021 Oct; 14(1):167. PubMed ID: 34649571
[TBL] [Abstract][Full Text] [Related]
18. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Zinzani PL; Mayer J; Flowers CR; Bijou F; De Oliveira AC; Song Y; Zhang Q; Merli M; Bouabdallah K; Ganly P; Zhang H; Johnson R; Martín García-Sancho A; Provencio Pulla M; Trněný M; Yuen S; Tilly H; Kingsley E; Tumyan G; Assouline SE; Auer R; Ivanova E; Kim P; Huang S; Delarue R; Trotman J
J Clin Oncol; 2023 Nov; 41(33):5107-5117. PubMed ID: 37506346
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
Gordon MJ; Feng L; Strati P; Lee HJ; Hagemeister FB; Westin JR; Samaniego F; Marques-Piubelli ML; Vega Vazquez F; Parra Cuentas ER; Solis-Soto LM; Ma W; Wang J; Claret L; Averill B; Ibanez K; Fayad LE; Flowers CR; Green MR; Davis RE; Neelapu SS; Fowler NH; Nastoupil LJ
Cancer; 2024 Mar; 130(6):876-885. PubMed ID: 37985359
[TBL] [Abstract][Full Text] [Related]
20. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
